http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36394159

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 575
issn 0009-9236
1532-6535
issueIdentifier 3
pageRange 565-575
publicationName Clinical pharmacology and therapeutics
startingPage 565
bibliographicCitation Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, Howe D, Gavala M, Killick H, Williams A, Krishnan S, Godwood A, Shukla A, Hewitt L, Lei A, Kell C, Pandya H, Newcombe P, White N, Scott IC, Cohen ES. A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease. Clin Pharmacol Ther. 2024 Mar;115(3):565–75. doi: 10.1002/cpt.3147. PMID: 38115209.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2af56b76714f203a31b5c7b50475fdc4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c7053d975cd1bd6b3ca52e5004e96344
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23dbb3299e3fbfa051655cabb5d50086
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3bcca4757b530996d8104154a481e698
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d0c9cb1aaea692d045e1e01d6ed1572
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48f80ac5e875ea8e44df28ebe20afbd9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d26f296882eaf15857be83221615d413
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55bd3f65981e00b093637190244043b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c772b379d3f1c27c6afb08856881a9b0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d98aa189b486a189981495ab1d77f23
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54f8eb31b1313d568ef0732e2771c3d7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_beae050c9377b2e781485e41532e7576
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37ad30930b052d11545819afe8abeded
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49a12b2bee77ccd9f4233ff1745777c8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7569e2fa8fa03f9c95035800bec9386c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fd86487ae6246239f52ca586aae70c2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1962517f7df297855290d1906f545c6f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e1d2cfdc285e22384e40b426d0e23dd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60c670da3efeb6abe1e2c3804c878045
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_735ba589798677df621efcb53d1fdd04
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2c3b9f071f896c2a04de3746c53a834
date 2024-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/38115209
https://doi.org/10.1002/cpt.3147
isPartOf https://portal.issn.org/resource/ISSN/0009-9236
https://portal.issn.org/resource/ISSN/1532-6535
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3058
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
discusses http://id.nlm.nih.gov/mesh/M0023752
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0024747
http://id.nlm.nih.gov/mesh/M000600385

Total number of triples: 44.